Back to List View Graph View

Chemoimmunotherapy

Chemoimmunotherapy is a cancer-treatment strategy that combines cytotoxic chemotherapy with immunotherapy, most commonly an immune checkpoint inhibitor or another immune-modulating treatment.

Where the papers sit

9 papers from the last 6 months study chemoimmunotherapy directly · updated from PubMed 16 Nov 2026

  • Clinical Outcomes Across Cancers

    Survival and progression-free survival anchor clinical chemoimmunotherapy reports in esophageal and head-and-neck squamous cancers, with adverse events and lymphopenia recurring. Stage IVB esophageal disease is evaluated with or without radiotherapy, while neoadjuvant afatinib is tested in locally advanced disease. Relapsed neuroblastoma extends the outcome focus beyond carcinoma and toward long-term survival. The set supports outcome benchmarking more than a single treatment direction.

    3 papers · 33.3%

  • Personalizing Lung Immunotherapy

    Biomarkers and treatment timing are becoming tools for selecting checkpoint-based therapy in lung cancer. ctDNA tumor fraction is examined for regimen selection in advanced NSCLC, while first-line chemoimmunotherapy timing is linked to survival in extensive-stage SCLC. The literature emphasizes progression-free survival and the uncertainty of whether these associations are predictive or merely prognostic. Validation remains necessary before ctDNA or circadian scheduling can guide routine care.

    3 papers · 33.3%

  • Targeted Combination Delivery

    Drug delivery is moving toward tumor-localized combinations that coordinate chemotherapy, immune activation and PD-L1 modulation. Engineered probiotics, copper complexes carrying PD-L1 plasmids, and hyaluronic-acid hydrogels with cisplatin and MSA-2 recur as delivery strategies. These platforms aim to improve tumor exposure, immunogenicity and the tumor microenvironment while limiting systemic toxicity. Evidence remains predominantly preclinical, leaving biodistribution, durability and clinical safety unresolved.

    3 papers · 33.3%

PARADIGM SHIFT

The efficacy of chemoimmunotherapy depends on when it is administered, not only on which agents it contains

The ES-SCLC timing cohort and the NSCLC LungTIME-C01 commentary both identify earlier administration as associated with substantially better progression-free and overall outcomes than later administration, challenging the assumption that chemoimmunotherapy is a time-invariant regimen whose efficacy is determined solely by its drugs. Treatment scheduling therefore becomes a potentially modifiable component of efficacy, although the NSCLC analysis notes that chemotherapy chronopharmacology, circadian immune regulation, and healthcare-delivery factors may also contribute 42788839Sep 42258320Jun.

NEW DIRECTION

Tumor-homing bacteria can function as an integrated in situ chemoimmunotherapy factory

The MC38 and B16-F10 murine tumor study used engineered Escherichia coli Nissle 1917 not merely as a carrier but as a living platform that converted 5-fluorocytosine into 5-fluorouracil while simultaneously producing an IL-15 superagonist and a PD-L1-blocking nanobody inside tumors. This assigns chemoimmunotherapy a new role as locally manufactured, self-targeted therapy capable of generating systemic antitumor immunity and durable immune memory, rather than as conventionally co-administered cytotoxic and immune-modulating drugs 42748218Sep.

Papers

The 9 papers from the last 6 months that study chemoimmunotherapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Clinical Outcomes Across Cancers (3)
  1. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
  2. Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. Future oncology (London, England) · 27 Jul 2026 PMID 42504461
  3. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
Personalizing Lung Immunotherapy (3)
  1. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
  2. Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
  3. Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
Targeted Combination Delivery (3)
  1. Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
  2. Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
  3. Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197

By study type

Clinical trials (1)
  1. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
Observational studies and case reports (3)
  1. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
  2. Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. Future oncology (London, England) · 27 Jul 2026 PMID 42504461
  3. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
Human data, design not indexed (2)
  1. Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
  2. Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
Preclinical: animal, cell and lab studies (3)
  1. Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
  2. Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
  3. Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197